Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Other Accumulated Expenses (2016 - 2025)

Historic Other Accumulated Expenses for Spyre Therapeutics (SYRE) over the last 11 years, with Q3 2025 value amounting to $170000.0.

  • Spyre Therapeutics' Other Accumulated Expenses fell 6768.06% to $170000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $170000.0, marking a year-over-year decrease of 6768.06%. This contributed to the annual value of $501000.0 for FY2024, which is 266.39% up from last year.
  • As of Q3 2025, Spyre Therapeutics' Other Accumulated Expenses stood at $170000.0, which was down 6768.06% from $242000.0 recorded in Q2 2025.
  • Over the past 5 years, Spyre Therapeutics' Other Accumulated Expenses peaked at $1.1 million during Q2 2021, and registered a low of $170000.0 during Q3 2025.
  • Moreover, its 5-year median value for Other Accumulated Expenses was $386000.0 (2023), whereas its average is $489352.9.
  • In the last 5 years, Spyre Therapeutics' Other Accumulated Expenses surged by 9782.02% in 2022 and then tumbled by 6768.06% in 2025.
  • Spyre Therapeutics' Other Accumulated Expenses (Quarter) stood at $783000.0 in 2021, then plummeted by 57.85% to $330000.0 in 2022, then surged by 47.88% to $488000.0 in 2023, then grew by 2.66% to $501000.0 in 2024, then crashed by 66.07% to $170000.0 in 2025.
  • Its Other Accumulated Expenses stands at $170000.0 for Q3 2025, versus $242000.0 for Q2 2025 and $371000.0 for Q1 2025.